Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023

Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023–January 2024

Published:2024-06 Issue:6 Volume:18 Page:
ISSN:1750-2640
Container-title:Influenza and Other Respiratory Viruses
language:en
Short-container-title:Influenza Resp Viruses

Author:

Paireau Juliette¹²^ORCID,Durand Cécile³^ORCID,Raimbault Sylvain⁴^ORCID,Cazaubon Joséphine¹,Mortamet Guillaume⁵^ORCID,Viriot Delphine¹^ORCID,Milesi Christophe⁶^ORCID,Daudens‐Vaysse Elise⁷,Ploin Dominique⁴^ORCID,Tessier Sabrina⁸^ORCID,Vanel Noémie⁹,Chappert Jean‐Loup¹⁰^ORCID,Levieux Karine¹¹^ORCID,Ollivier Ronan¹²,Daoudi Jamel¹³,Coignard Bruno¹^ORCID,Leteurtre Stéphane¹⁴,Parent‐du‐Châtelet Isabelle¹^ORCID,Vaux Sophie¹^ORCID

Affiliation:

1. Direction des maladies infectieuses Santé publique France Saint‐Maurice France

2. Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur Université Paris Cité, CNRS UMR 2000 Paris France

3. Cellule Régionale Occitanie Santé publique France Toulouse France

4. Service de Réanimation et Urgences Pédiatriques Hôpital Femme Mère Enfant, Hospices Civils de Lyon Bron France

5. Service de soins critiques pédiatriques CHU Grenoble‐Alpes Grenoble France

6. Service de Réanimation pédiatrique Hôpital Arnaud de Villeneuve Montpellier France

7. Cellule Régionale Hauts‐de‐France Santé publique France Lille France

8. Cellule Régionale Bourgogne‐Franche‐Comté Santé publique France Lille France

9. Service de Réanimation pédiatrique CHU de La Timone Marseille France

10. Cellule Régionale Occitanie Santé publique France Montpellier France

11. Services d'urgences pédiatriques Centre Hospitalier Universitaire de Nantes Nantes France

12. Cellule Régionale Pays de la Loire Santé publique France Nantes France

13. Cellule Océan Indien Santé publique France Saint‐Denis France

14. Réanimation et Soins Intensifs Pédiatriques Polyvalents, CHU Lille Université de Lille, ULR 2694 – METRICS: Évaluation des technologies de santé et des pratiques médicales Lille France

Abstract

ABSTRACTIn September 2023, France was one of the first countries that started a national immunisation campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of paediatric intensive care units (PICUs), we aimed to estimate nirsevimab effectiveness against severe cases of RSV bronchiolitis in France. We conducted a case–control study based on the test‐negative design and included 288 infants reported by 20 PICUs. We estimated nirsevimab effectiveness at 75.9% (48.5–88.7) in the main analysis and 80.6% (61.6–90.3) and 80.4% (61.7–89.9) in two sensitivity analyses. These real‐world estimates confirmed the efficacy observed in clinical studies.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.13311

Reference15 articles.

1. Seasonal and inter‐seasonal RSV activity in the European Region during the COVID‐19 pandemic from autumn 2020 to summer 2022

2. Bronchiolitis epidemics in France during the SARS-CoV-2 pandemic: The 2020–2021 and 2021–2022 seasons

3. Santé publique France “Bulletin épidémiologique bronchiolite. Bilan de la surveillance 2022–2023 ” accessed March 5 2024 https://www.santepubliquefrance.fr/maladies‐et‐traumatismes/maladies‐et‐infections‐respiratoires/bronchiolite/documents/bulletin‐national/bulletin‐epidemiologique‐bronchiolite.‐bilan‐de‐la‐surveillance‐2022‐2023.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bronchiolite : stratégie de prévention pour l’hiver 2024–2025;Perfectionnement en Pédiatrie;2024-09

2. Nirsevimab: Alleviating the burden of RSV morbidity in young children;Journal of Paediatrics and Child Health;2024-08-16

3. Nirsevimab—a breakthrough in respiratory syncytial virus bronchiolitis;The Lancet Child & Adolescent Health;2024-08

4. Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case–control study in Paris, France;The Lancet Child & Adolescent Health;2024-08

5. Independent Analysis of the Results of the First Infant Immunization Campaign with Beyfortus® (Nirsevimab, Monoclonal Antibody Against RSV Bronchiolitis Virus): Mixed Results, Identification of Biases, and Possible Role and Mechanisms of ADE (Antibody Dependent Enhancement);2024-06-11